Vitrolife has appointed the Board member Fredrik Mattsson as head of the newly established New Business and Strategic Development function in order to strengthen the company’s business development. In conjunction with the new operative role, Fredrik Mattsson is stepping down as a Board member of Vitrolife AB and Henrik Blomquist, CEO of Bure Equity AB, will assume the role of co-opted Board member up until the next Annual General Meeting.
Fredrik Mattsson has many years’ experience of business development, for example in the medical device sector, and takes up his new position on September 15. When he takes up this position he will step down from his employment as Investment Director at Bure Equity AB. The newly established New Business and Strategic Development function aims to support the company’s growth strategy and Fredrik Mattsson will be part of the company’s executive management.
September 12, 2018
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Carsten Browall, Chairman of the Board, tel 46 702 55 65 32
This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on September 12, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.